Federal Register / Vol. 79, No. 227 / Tuesday, November 25, 2014 / Notices 70195 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name 

Estimated 

annual 

number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total annual 

burden hours 

Laboratory Personnel Using Bulk Submission ..... Minimal Fields .............. 190 29 18/60 1,653 

Optional Fields ............. 159 29 14/60 1,076 

Laboratory Personnel Not Using Bulk Submission.Minimal Fields .............. 116 29 30/60 1,682 

Optional Fields ............. 97 29 24/60 1,125 

Dated: November 17, 2014. 

Lawrence A. Tabak, 

Principal Deputy Director, National Institutes 

of Health. 

[FR Doc. 2014–27898 Filed 11–24–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 209 and 37 CFR part 404 to 

achieve expeditious commercialization 

of results of federally-funded research 

and development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information and copies of the 

U.S. patent applications listed below 

may be obtained by writing to the 

indicated licensing contact at the Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301– 

496–7057; fax: 301–402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

SUPPLEMENTARY INFORMATION: 

Technology descriptions follow. 

T-cell Chimeric Receptors of TSLPR for 

Diagnosis and Immunotherapy of 

Cancer 

Description of Technology: T-cellbased immunotherapies allow a 

patient’s immune system to concentrate 

its efforts and destroy cancer cells. In 

the present technology, the researchers 

at the National Cancer Institute have 

developed chimeric antigen receptors 

(or CARs), which encode an antigen 

binding domain specific for thymic 

stromal lymphopoietin receptor 

(TSLPR) and a T-cell signaling domain. 

TSLPR is over-expressed on the surface 

of approximately 10% of adult and 

pediatric B-cell precursor acute 

lymphoblastic leukemias (BCP–ALL). 

Available for licensing is the abovereference CAR technology as well as 

methods for diagnosing and treating 

cancer using these CARs. 

Potential Commercial Applications: 

• Immunotherapy against cancer, 

especially leukemia 

• Immunotoxins 

Competitive Advantages: CAR 

receptors are specific for TSLPR. 

Development Stage: 

• In vitro data available 

• In vivo data available (animal) 

• Prototype 

Inventors: Terry Fry and Haiying Qin 

(NCI). 

Publication: Qin H, et al. Pre-clinical 

development of a novel chimerical 

antigen receptor targeting high-risk 

pediatric ALL over-expressing Tslpr. 

Blood 2013 Nov 15;122(21):2665. 

Intellectual Property: 

• HHS Reference No. E–008–2014/0— 

US Provisional Application No. 61/ 

912,948 filed 06 Dec 2013 

• HHS Reference No. E–008–2014/1— 

US Provisional Application No. 61/ 

991,697 filed 12 May 2014 

• HHS Reference No. E–008–2014/2— 

PCT Application No. PCT/US2014/ 

063096 filed 30 Oct 2014 

Licensing Contact: Patrick McCue, 

Ph.D.; 301–435–5560; mccuepat@

mail.nih.gov 

Novel Bridged Bicyclic Thiazepinone 

Compounds 

Description of Technology: The 

invention is directed to small molecules 

containing a novel, bridged, bicyclic 

thiazepinone pharmacophore. Invention 

compounds inhibit the Nav1.7 sodium 

channel. Additionally, invention 

compounds bind the human 

norepinephrine transporter (NET), with 

selectivity over the serotonin transporter 

(SERT) and dopamine transporter 

(DAT). 

Invention compounds could be used 

to treat neuropathic pain associated 

with diabetes and fibromyalgia, 

Attention Deficit Hyperactivity Disorder 

(ADHD), urinary incontinence, 

depression, anxiety, and other mood 

disorders. 

Invention compounds can be 

conjugated with fluorescent or 

radioactive tags, and used to probe the 

structure and activity of the Nav1.7 

sodium channel and NET. 

Potential Commercial Applications: 

• Therapeutic 

• Chemical probe 

Competitive Advantages: 

• Small molecule compounds made 

using facile synthesis scheme 

• Inhibition of Nav1.7 sodium channel 

• NET inhibition with selectivity over 

other transporters 

Development Stage: 

• Early-stage 

• In vitro data available 

Inventors: Hans F. Luecke (NIDDK), 

Michael T. Scerba (NIDDK), Dongwook 

Kang (Daegu Catholic University). 

Intellectual Property: HHS Reference 

No. E–224–2012/0— 

• US Application No. 61/876,262 filed 

09 Sept 2013 

• PCT Application No. PCT/US2014/

054660 filed 09 Sept 2014 

Licensing Contact: Lauren NguyenAntczak, Ph.D., J.D.; 301–435–4074; 

nguyenantczakla@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Diabetes and 

Digestive and Kidney Diseases is 

seeking statements of capability or 

interest from parties interested in 

collaborative research to further 

develop, evaluate or commercialize use 

of bridged bicyclic thiazepinones. For 

collaboration opportunities, please 

contact Marguerite J. Miller, M.B.A. at 

marguerite.miller@nih.gov or 301–496– 

9003. 


wreier-aviles on DSK4TPTVN1PROD with NOTICES
70196 Federal Register / Vol. 79, No. 227 / Tuesday, November 25, 2014 / Notices 

Dated: November 18, 2014. 

Richard U. Rodriguez, 

Acting Director, Office of Technology 

Transfer, National Institutes of Health. 

[FR Doc. 2014–27820 Filed 11–24–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Topics in 

Clinical Research and Field Studies of 

Infectious Diseases. 

Date: December 2, 2014. 

Time: 4:00 p.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Soheyla Saadi, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3211, 

MSC 7808, Bethesda, MD 20892, 301–435– 

0903, saadisoh@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Development and Testing of Novel 

Interventions to Improve HIV Prevention, 

Care and Program Implementation. 

Date: December 3, 2014. 

Time: 2:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Mark P. Rubert, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5218, 

MSC 7852, Bethesda, MD 20892, 301–435– 

1775, rubertm@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA Panel: 

Tobacco Control Regulatory Research. 

Date: December 4, 2014. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Institutes of Health, 

6701 Rockledge Drive, 

Bethesda, MD 20892. 

Contact Person: Mark P. Rubert, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5218, 

MSC 7852, Bethesda, MD 20892, 301–435– 

1775, rubertm@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; RFA Panel: 

Tobacco Control Regulatory Research. 

Date: December 5, 2014. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Washington Marriott at Metro 

Center, 775 12th St. NW., Washington, DC 

20005. 

Contact Person: Shiv A. Prasad, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5220, 

MSC 7852, Bethesda, MD 20892, 301–443– 

5779, prasads@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: AIDS and AIDS Related Research. 

Date: December 8–9, 2014. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Robert Freund, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5216, 

MSC 7852, Bethesda, MD 20892, 301–435– 

1050, freundr@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: HIV/AIDS Innovative Research 

Applications. 

Date: December 8, 2014. 

Time: 11:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Mark P. Rubert, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5218, 

MSC 7852, Bethesda, MD 20892, 301–435– 

1775, rubertm@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Program 

Project: AIDS and AIDS Related Research. 

Date: December 9, 2014. 

Time: 1:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Virtual Meeting). 

Contact Person: Kenneth A. Roebuck, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5106, 

MSC 7852, Bethesda, MD 20892, (301) 435– 

1166, roebuckk@csr.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: November 19, 2014. 

David Clary, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–27818 Filed 11–24–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Institute on 

Aging Special Emphasis Panel, 

November 17, 2014, 11:00 a.m. to 

November 17, 2014, 03:00 p.m., 

National Institute on Aging, Gateway 

Building, 7201 Wisconsin Avenue, Suite 

2C212, Bethesda, MD 20892 which was 

published in the Federal Register on 

September 17, 2014 (79 FR 55817). 

The meeting notice is amended to 

change the date of the meeting from 

November 17, 2014 to December 8, 2014 

at 12:00 p.m. to 4:00 p.m. The meeting 

is closed to the public. 


wreier-aviles on DSK4TPTVN1PROD with NOTICES